PerkinElmer Launches New Assay Development Service for ...

PerkinElmer, Inc. , a global technology leader in Health Sciences and Photonics, today announced the launch of a comprehensive assay development service for high-performance, highly sensitive assays in advanced cellular science and drug discovery research.

"Whether it's developing custom assays, increasing assay densities from 96- to 384- or 1536-well, or converting outdated assay technologies to next-generation platforms, our assay development service can fast-track development of application-specific assays for pharmaceutical and research customers, saving them time and money and letting them concentrate on analyzing results instead of setting up experiments," said Richard Eglen, Vice President and General Manager of the Discovery and Research Reagents business of PerkinElmer Life and Analytical Sciences. "The service brings together PerkinElmer's industry-leading advanced technologies, our deep expertise in high throughput screening, and our recognized commitment to service to ensure success for our customers in their important research."

Assay Development Services for High-Value Targets

The new service offers comprehensive assay solutions for high-value g-protein coupled receptor (GPCR) and kinase cell-based screening including highly sensitive, high throughput platforms such as the AlphaScreen(R), AequoScreen(R), DELFIA(R), and LANCE(R) technologies.

GPCR and protein kinases actively signal and regulate several important functions within cells, presenting a wide range of therapeutic targets in areas including cancer, central nervous system disorders, cardiac dysfunction, and diabetes, making them among the most important areas of study in today's pharmaceutical and biotech laboratories.

Optimized reporter gene assays are available utilizing steadylite plus(TM) and britelite plus(TM) technologies. In addition to cell-based GPCR and kinase assays, the service also offers biochemical enzyme and radioligand binding assays on the FlashPlate(R) or Image FlashPlate(R) platforms in 384-well or 96-well formats.

The assay development service will also provide miniaturization of tough-to-automate immunoassays. PerkinElmer's AlphaLISA(TM) technology offers a homogenous alternative to traditional enzyme-linked immunosorbent assays (ELISAs), enabling labs to easily automate these assays for greater productivity and throughput while achieving higher sensitivity, a wider dynamic range and therefore more relevant data. The service will facilitate a seamless conversion from ELISA to this new enabling technology.

Consultative Development Process

Following scientific consultation with the laboratory, PerkinElmer will propose development and validation studies and cost estimates. The studies may include anything from initial assay formatting and feasibility, to optimization of the assay protocol for robustness, to validation of performance characteristics such as reproducibility. During this, and other milestone phases, PerkinElmer works closely with laboratories to maintain a workable balance between cost and technical objectives. PerkinElmer assay development typically takes two to four weeks. Subsequent training, assay transfer and validation at the customer site are supported by PerkinElmer's scientists.

For more information on PerkinElmer's GPCR, kinase or biomarker assays, or its customized assay development service, visit PerkinElmer online at: www.perkinelmer.com, or contact a PerkinElmer sales representative.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com